ArticleThoracic cancer2021
Estimated direct costs of non-small cell lung cancer by stage at diagnosis and disease management phase: A whole-disease model.
Article in Thoracic cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic Literature Review to Identify Cost and Resource Use Data in Patients with Early-Stage Non-small Cell Lung Cancer (NSCLC).PharmacoEconomics · 2023Pooled it
- [Implementation of a national lung cancer screening in Austria : Position paper of the Austrian Radiological Society (ÖRG), the Austrian Society of Pneumology (ÖGP), the Austrian Society of General Practice and Family Medicine (ÖGAM) and the Austrian Society of Thoracic Surgery (ÖGTC)].Wiener klinische Wochenschrift · 2026Article
- Estimating stage-specific lung cancer costs for economic evaluation of LDCT screening in Ireland: a patient-level microsimulation.BMC health services research · 2026Article
- Change in healthcare resource use and associated costs of patients with metastatic lung cancer between 2013 and 2021: an observational study from the French national health data system.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Observational
- Lung Cancer Screening in a Population from Northeast Italy Exposed to Both Asbestos and Smoking: A Cost-Effectiveness Analysis.Journal of clinical medicine · 2026Article
- Comparison of prognosis between patients undergoing surgical resection and stereotactic ablative radiotherapy for early-stage lung cancer.BMC cancer · 2026Article
- Direct economic burden of 0.9 million hospitalized cancer patients in Shenzhen, China, 2016-2022.BMC health services research · 2026Article
- Article
- Article
- Estimating surgery, radiotherapy and systemic anti-cancer therapy treatment costs for cancer patients by stage at diagnosis.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Article
- New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe.The Lancet regional health. Europe · 2024Review
- Cost-consequence analysis of the enhanced recovery after surgery protocol in major lung resection with minimally invasive technique (VATS).Frontiers in surgery · 2024Article
- Advancing early access policies for innovative cancer drugs: a scoping review and explorative analysis in the Italian setting.Journal of pharmaceutical policy and practice · 2024Article
- Canadian Consensus Recommendations for the Management of Operable Stage II/III Non-Small-Cell Lung Cancer: Results of a Modified Delphi Process.Current oncology (Toronto, Ont.) · 2023Article
- Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain.BMC pulmonary medicine · 2023Article
- Transbronchial brushing cytology and paired biopsy in endobronchial tuberculosis: A report of 72 cases focusing on the morphological features.CytoJournal · 2023Article
- Cost-effectiveness analysis of the new oncological drug durvalumab in Italian patients with stage III non-small cell lung cancer.Thoracic cancer · 2022Article
- Response to: Estimated direct costs of non-small cell lung cancer by stage at diagnosis and disease management phase: A whole-disease model.Thoracic cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-small cell lung cancer (NSCLC) is the first cause of cancer-related death among men and the second among women worldwide. It also poses an economic threat to the sustainability of healthcare services. This study estimated the direct costs of care for patients with NSCLC by stage at diagnosis, and management phase of pathway recommended in local and international guidelines.
methodsBased on the most up-to-date guidelines, we developed a very detailed "whole-disease" model listing the probabilities of all potentially necessary diagnostic and therapeutic actions involved in the management of each stage of NSCLC. We assigned a cost to each procedure, and obtained an estimate of the total and average per-patient costs of each stage of the disease and phase of its management.
resultsThe mean expected cost of a patient with NSCLC is 21,328 € (95% C.I. -20 897-22 322). This cost is 16 291 € in stage I, 19530 € in stage II, 21938 € in stage III, 22175 € in stage IV, and 28 711 € for a Pancoast tumor. In the early stages of the disease, the main cost is incurred by surgery, whereas in the more advanced stages radiotherapy, medical therapy, treatment for progressions, and supportive care become variously more important.
conclusionsAn estimation of the direct costs of care for NSCLC is fundamental in order to predict the burden of new oncological therapies and treatments on healthcare services, and thus orient the decisions of policy-makers regarding the allocation of resources. KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: The high costs of surgery make the early stages of the disease no less expensive than the advanced stages. WHAT THIS STUDY ADDS: An estimation of the direct costs of care is fundamental in order to orient the decisions of policy-makers regarding the allocation of resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.